Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
16918 results about "Pathology" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Pathology is the study of the causes and effects of disease or injury. The word pathology also refers to the study of disease in general, incorporating a wide range of bioscience research fields and medical practices. However, when used in the context of modern medical treatment, the term is often used in a more narrow fashion to refer to processes and tests which fall within the contemporary medical field of "general pathology", an area which includes a number of distinct but inter-related medical specialties that diagnose disease, mostly through analysis of tissue, cell, and body fluid samples. Idiomatically, "a pathology" may also refer to the predicted or actual progression of particular diseases (as in the statement "the many different forms of cancer have diverse pathologies"), and the affix path is sometimes used to indicate a state of disease in cases of both physical ailment (as in cardiomyopathy) and psychological conditions (such as psychopathy). A physician practicing pathology is called a pathologist.
Compositions and methods for treating and diagnosing cancer
InactiveUS20060019256A1Reduce the amount requiredMicrobiological testing/measurementAntiinfectivesSolid tumorCancer research
The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides gene expression profiles associated with solid tumor stem cells, as well as novel stem cell cancer markers useful for the diagnosis, characterization, and treatment of solid tumor stem cells.
Owner:RGT UNIV OF MICHIGAN
PD-1 Antibodies and PD-L1 Antibodies and Uses Thereof
ActiveUS20120039906A1Reduced activityStrong cytotoxicityAntibacterial agentsAnimal cellsPD-L1Antibody
Owner:INST JEAN PAOLI & IRENE CALMETTES +2
Methods, systems, and associated implantable devices for dynamic monitoring of physiological and biological properties of tumors
InactiveUS6402689B1Enhanced and favorable treatmentMinimize couplingMechanical/radiation/invasive therapiesSurgeryDynamic monitoringEngineering
Methods of monitoring and evaluating the status of a tumor undergoing treatment includes monitoring in vivo at least one physiological parameter associated with a tumor in a subject undergoing treatment, transmitting data from an in situ located sensor to a receiver external of the subject, analyzing the transmitted data, repeating the monitoring and transmitting steps at sequential points in time and evaluating a treatment strategy. The method provides dynamic tracking of the monitored parameters over time. The method can also include identifying in a substantially real time manner when conditions are favorable for treatment and when conditions are unfavorable for treatment and can verify or quantify how much of a known drug dose or radiation dose was actually received at the tumor. The method can include remote transmission from a non-clinical site to allow oversight of the tumor's condition even during non-active treatment periods (in between active treatments). The disclosure also includes monitoring systems with in situ in vivo biocompatible sensors and telemetry based operations and related computer program products.
Owner:NORTH CAROLINA STATE UNIV +1
Compositions for targeting the vasculature of solid tumors
InactiveUS6051230AEffectively compete for bindingReduce TEC-4 or TEC-11 bindingHybrid immunoglobulinsPeptide/protein ingredientsAntigenCell Surface Antigens
The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the vasculature of solid tumor masses through recognition of tumor vasculature-associated antigens, such as, for example, through endoglin binding, or through the specific induction of endothelial cell surface antigens on vascular endothelial cells in solid tumors.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Device and method for attenuating an immune response
ActiveUS20050075701A1Good flexibilityMore levelsSpinal electrodesImplantable neurostimulatorsNervous systemNeuron
Stimulation of one or more neurons of the sympathetic nervous system, including the splenic nerve, to attenuate an immune response, including an inflammatory immune response, is discussed. Devices and systems to stimulate the sympathetic nervous system to attenuate an immune response are also discussed. Devices discussed include pulse generators and drug pumps. Systems are described as optionally having one or more sensors and operator instructions. In specific examples, stimulation of the splenic nerve of pigs with a pulse generator is shown to be safe and effective in attenuating a lipopolysaccharide-induced immune response.
Owner:MEDTRONIC INC
FcgammaRIIB-specific antibodies and methods of use thereof
ActiveUS20040185045A1Strong therapeutic activityEnhancing antibody-mediated effector functionSenses disorderAntipyreticTherapeutic antibodyTreatment effect
The present invention relates to antibodies or fragments thereof that specifically bind FcgammaRIIB, particularly human FcgammaRIIB, with greater affinity than said antibodies or fragments thereof bind FcgammaRIIA, particularly human FcgammaRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
Owner:MACROGENICS INC
Cord blood and placenta collection kit
ActiveUS7147626B2Bioreactor/fermenter combinationsBiological substance pretreatmentsCord blood stem cellPhysiology
The present invention provides an improved kit for the collection of umbilical cord blood and placental blood, and collection of the placenta from which such blood is obtained. The kit improves upon existing kits in that it provides for improved user convenience, provides for the collection of the placenta itself, and better maintains the internal temperature of the container in which the collected blood and placenta are shipped to a blood bank or registry. The invention further provides a method of collecting umbilical cord and placental blood, and the placenta from which such blood is obtained, comprising using the kit described herein.
Owner:CELULARITY INC
Cartilage and bone repair and regeneration using postpartum-derived cells
Cells derived from postpartum tissue and methods for their isolation and induction to differentiate to cells of a chondrogenic or osteogenic phenotype are provided by the invention. The invention further provides cultures and compositions of the postpartum-derived cells and products related thereto. The postpartum-derived cells of the invention and products related thereto have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications, for example, in the treatment of bone and cartilage conditions.
Owner:DEPUY SYNTHES PROD INC
Hyperspectral/multispectral imaging in determination, assessment and monitoring of systemic physiology and shock
ActiveUS20070024946A1Reduce and present informationHigh indexRadiation pyrometryDiagnostics using lightWhole bodyBurn shock
The present invention provides a hyperspectral imaging system which demonstrates changes in tissue oxygen delivery, extraction and saturation during shock and resuscitation including an imaging apparatus for performing real-time or near real-time assessment and monitoring of shock, including hemorrhagic, hypovolemic, cardiogenic, neurogenic, septic or burn shock. The information provided by the hyperspectral measurement can deliver physiologic measurements that support early detection of shock and also provide information about likely outcomes.
Owner:HYPERMED IMAGING
Transfection of blood cells with mRNA for immune stimulation and gene therapy
InactiveUS20060188490A1Improve stabilityIncrease transfectionSsRNA viruses negative-senseBiocideAntigenCancer prevention
The present invention relates to a pharmaceutical composition containing blood cells or haemopoietic cells, e.g. red blood cells (erythrocytes), granulocytes, mononuclear cells (PBMCs) and / or blood platelets, in combination with a pharmaceutically acceptable excipient and / or vehicle, wherein the cells are transfected with at least one mRNA comprising at least one region coding for at least one antigen. The invention further discloses a method of preparing the aforesaid pharmaceutical composition and the use of blood cells transfected in this way for the preparation of drugs or pharmaceutical compositions for immune stimulation against the antigens encoded by the mRNA. The subjects according to the invention are used especially for the therapy and / or prophylaxis of carcinoses or infectious diseases and can also be employed in gene therapy.
Owner:CUREVAC AG
Blood Analyte Determinations
InactiveUS20070225675A1Accurate measurementIncreased risk of infectionHaemofiltrationMedical devicesAnalyteMedicine
The present invention comprises methods and apparatuses that can provide measurement of glucose and other analytes with a variety of sensors without many of the performance-degrading problems of conventional approaches. As apparatus according to the present invention comprises a blood access system, adapted to remove blood from a body and infuse at least a portion of the removed blood back into the body. Such an apparatus also comprises an analyte sensor, mounted with the blood access system such that the analyte sensor measures the analyte in the blood that has been removed from the body by the blood access system. A method according to the present invention comprises removing blood from a body, using an analyte sensor to measure an analyte in the removed blood, and infusing at least a portion of the removed blood back into the body. The use of a non-contact sensor with a closed system creates a system will minimal infection risk.
Owner:ROBINSON MARK RIES +5
Multipotent amniotic fetal stem cells
A source of multipotent amniotic fluid / fetal stem cells (MAFSCs) is disclosed. MAFSC are of fetal origin and have a normal diploid karyotype. These cells are characterized by the following cell surface markers: SSEA3, SSEA4, Tra-1-60, Tra-1-81, Tra-2-54, HLA class I, CD13, CD44, CD49b, CD105 and are distinguished by the absence of the antigen markers CD34, CD45, and HLA Class II, but are distinguished from mouse embryonic stem cells in that these cells do not express the cell surface marker SSEA1. MAFSC express the stem cell transcription factor Oct-4. MAFSC cells can be propagated for an indefinite period of time in continuous culture in an undifferentiated state. The MAFSCs have the ability to differentiate in culture in a regulated manner, into three or more subphenotypes. Cells can then be differentiated into endodermal, mesodermal and ectodermal derived tissues in vitro and in vivo. A method for isolating, identifying, expanding and differentiating MAFSCs is disclosed.
Owner:RGT UNIV OF CALIFORNIA
Uses and compositions for treatment of rheumatoid arthritis
ActiveUS20080166348A1Relieve symptomsInhibit progressSsRNA viruses negative-senseBiocideAntigen bindingRheumatoid arthritis
The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of rheumatoid arthritis in a subject.
Owner:ABBVIE BIOTECHNOLOGY LTD
Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
InactiveUS6972013B1Formidable physical barrier to gene transferHigh expressionElectrotherapyMedical devicesWhole bodyIn vivo
In vivo methods are provided for using an electric field to delivery therapeutic or immunizing treatment to a subject by applying non-invasive, user-friendly electrodes to the surface of the skin. Thus, therapeutic or immunizing agents can be delivered into cells of skin for local and systemic treatments or for immunization with optimal gene expression and minimal tissue damage. In particular, therapeutic agents include naked or formulated nucleic acid, polypeptides and chemotherapeutic agents.
Owner:INOVIO PHARMA
Micrornas and uses thereof
Described herein are novel polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.
Owner:ROSETTA GENOMICS
Systems and methods for treating patients with processed lipoaspirate cells
Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.
Owner:VERIZON LAB +1
EGFR mutations
The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and / or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.
Owner:GENENTECH INC
Antibiotic treatment of age-related macular degeneration
InactiveUS6015803AImprove visual acuityBiocideTetracycline active ingredientsAntibiotic YMacrolide resistance
A method is provided for the treatment of age-related macular degeneration by administering various antibiotics, such as tetracycline and its derivatives, rifamycin and its derivatives, macrolides, and metronidazole, to a patient in a therapeutically effective amount.
Owner:WIROSTKO BARBARA
Method of treating depression using a TNF-alpha antibody
InactiveUS20070041905A1Inhibiting TNFα activityImprove depressionSalicyclic acid active ingredientsBiocideAntiendomysial antibodiesAntigen binding
The invention describes methods of treating depression comprising administering a TNFα antibody, such as a human TNFα antibody. The invention also provides a method for treating depression comprising inhibiting TNFα activity in a subject suffering from depression by systemically administering to the subject a human anti-TNFα antibody, or an antigen-binding portion thereof, such that depression is treated. Also described is a method for the treatment or alleviation of depression or other affective disorders comprising administering an amount of an anti-inflammatory agent effective to treat or alleviate depression or other affective disorder to a subject in need thereof, wherein said anti-inflammatory agent down-regulates peripheral cytokine levels to thereby treat or alleviate depression or other affective disorder.
Owner:HOFFMAN REBECCA S +3
Fcgamma riib specific antibodies and methods of use thereof
InactiveUS20050215767A1Enhance immune responseImprove responseSenses disorderAntipyreticTherapeutic antibodyAntiendomysial antibodies
Owner:MACROGENICS INC
Methods and compositions for organ and tissue functionality
Materials and methods for treating tissue defects in human or animal tissues using implantable cells are described. Further, culture techniques and factors for enhancing these procedures, and cell survival and adaptation are described. Many of the tissue defects may be treated with autologous cells, while applications involving non-autologous cells or stem cells are also described.
Owner:DASK TECH
Methods and compositions for the treatment of persistent infections
ActiveUS20070122378A1Reduced activityReduce expressionAntibacterial agentsOrganic active ingredientsMicrobiologyPathology
The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.
Owner:DANA FARBER CANCER INST INC +3
Compositions of PD-1 antagonists and methods of use
InactiveUS8114845B2Improve responseInhibitory signal transductionAntibacterial agentsOrganic active ingredientsCompound (substance)T cell
Owner:MEDIMMUNE LLC
Anti-VEGF antibodies
ActiveUS20070020267A1Inhibit bindingSenses disorderImmunoglobulins against growth factorsAnti vegf antibodyBacteriophage
Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
Owner:GENENTECH INC
Compensation of human variability in pulse oximetry
Owner:DATEX OHMEDA
Method and apparatus for heating inflammed tissue
The present invention relates to methods for treating inflammation in body tissues. More specifically, certain disclosed methods relate to selectively inducing apoptosis in inflammatory immune cells by heating cells for a sufficient time and at a sufficient temperature to induce programmed cell death. The disclosed stents can be placed in contact with the inflammatory cells and heated under controlled conditions. The disclosed apparatus and methods are particularly suitable for treating athersclerotic plaques.
Owner:TEXAS HEART INST +1
Apparatus and formulations for suprachoroidal drug delivery
InactiveUS20070202186A1Avoid traumaMinimally-invasive deliveryBiocidePowder deliveryPosterior regionPharmaceutical formulation
Drug formulations, devices and methods are provided to deliver biologically active substances to the eye. The formulations are delivered into scleral tissues adjacent to or into the suprachoroidal space without damage to the underlying choroid. One class of formulations is provided wherein the formulation is localized in the suprachoroidal space near the region into which it is administered. Another class of formulations is provided wherein the formulation can migrate to another region of the suprachoroidal space, thus allowing an injection in the anterior region of the eye in order to treat the posterior region.
Owner:CLEARSIDE BIOMEDICAL
Non-invasive method to detect prostate cancer
InactiveUS6383759B1Microbiological testing/measurementImmunoglobulinsAbnormal tissue growthNon invasive
Owner:GERALD P MURPHY CANCER FOUND
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com